The high-affinity receptor for immunoglobulin (Ig) E (FceRl) on mast cells and basophils plays a key role in IgE-mediated allergies. FceRI is composed of one ix, one [3, and two ",/ chains, which are all required for cell surface expression of FceRI, but only the ci chain is involved in the binding to IgE. FceRI-IgE interaction is highly species specific, and rodent FceRI does not bind human IgE. To obtain a "humanized" animal model that responds to human IgE in allergic reactions, transgenic mice expressing the human FceRI ix chain were generated. The human FceRI ix chain gene with a 1.3-kb promoter region as a transgene was found to be sufficient for mast cell-specific transcription. Cell surface expression of the human FceRI ix chain was indicated by the specific binding of human IgE to mast cells from transgenic mice in flow cytometric analyses. Expression of the transgenic FceRI on bone marrow-derived mast cells was 4.7 • 104/ce11, and the human IgE-binding affinity was K d = 6.4 nM in receptor-binding studies using 12sI-IgE. The transgenic human FceRI ix chain was complexed with the mouse [3 and ",/chains in immunoprecipitation studies. Cross-linking of the transgenic FceRI with human IgE and antigens led to mast cell activation as indicated by enhanced tyrosine phosphorylation of the FceRI [3 and ~/chains and other cellular proteins. Mast cell degranulation in transgenic mice could be triggered by human lgE and antigens, as demonstrated by [3-hexosaminidase release in vitro and passive cutaneous anaphylaxis in vivo. The results demonstrate that the human FceRI ix chain alone not only confers the specificity in human IgE binding, but also can reconstitute a functional receptor by coupling with the mouse [3 and y chains to trigger mast cell activation and degranulation in a whole animal system. These transgenic mice "humanized" in IgE-mediated allergies may be valuable for development of therapeutic agents that target the binding of IgE to its receptor.
I
gE antibodies, mast cells, and basophils play a pivotal role in allergic responses (1, 2). Exposure of an individual to allergens induces the production of allergen-specific IgE antibodies. Mast cells and basophils bind monomeric IgE via the high-affinity IgE receptor (FceRI) 1 (1, 2). Subsequent exposure to allergens results in cross-linking of receptor-bound IgE on mast cells and basophils, leading to cellular activation and degranulation (1, 2). The release of a 1Abbreviations used in this paper: BMMC, bone marrow-derived mast cells; DNP, dinitrophenyl; FceRI, high-affinity IgE receptor; NIP, nitro-iodohydroxyphenyl.
variety of potent mediators, such as histamine, proteases, and arachidonic acid metabolites, accounts for many of the symptoms in allergies (3, 4) .
Fc~RI has been suggested to be the key receptor in IgEmediated mast cell exocytosis (1, 2). This notion is supported by the finding that gene-targeted mice defective in Fc~RI expression are resistant to IgE-mediated anaphylaxis (5) . Fc~RI is a tetrameric receptor composed of one ix, one [3, and two disulfide-linked ~/ chains (1). Previous in vitro studies suggest that the binding of Fc~RI to IgE is mediated by the ix chain (6) (7) (8) . However, cell surface expression of FceRI requires the presence of all three subunits (9, 10) . Fc~RI is expressed not only on mast cells, basophils, and eosinophils, but also on monocytes and Langerhans cells (2, 
11-15), suggesting functions in addition to mediating degranulation.
Human IgE is highly species specific and does not crossreact with rodent receptors (6) . To obtain an animal model capable of responding to human IgE in allergic reactions, we generated transgenic mice expressing the human FceRI ci chain. Our study showed that the human oL chain of FceRI alone can reconstitute a functional receptor in mice. These transgenic mice can respond to human igE in allergic reactions.
Materials and Methods

Generation of Transgenic Mice Expressing the Human High-Affinity
IgE Receptor oe Chain. The human genomic clone for the FceRI c~ chain that we reported previously (16) was used to construct the transgene. An 11.4-kb human genomic DNA fragment in the clone covering the entire structural gene plus a 1.3-kb promoter region and a 4.2-kb 3' flanking region was injected into mouse embryos to generate transgenic mice. The transgene in mice was confirmed by DNA hybridization. Mouse tail DNA was digested with EcoRI and hybridized to the previously reported human Fc~RI a chain cDNA (16) . Transgenic founders identified by hybridization were then bred with C57BL/6J mice to obtain transgenic offspring for phenotypic and functional studies.
Detection of Transgenic mRNA. Total RNA was isolated from bone marrow-derived mast cells (BMMC) and from mouse organs according to the method described previously (16) . The organs used in RNA extraction included heart, kidney, liver, spleen, stomach, and skin. mRNA encoding the human FceRI 0~ chain was detected by Northern blot hybridization using the previously reported human FceRI cr chain cDNA as a probe (16) . mRNA for the mouse FceRl c~ chain was detected by the oligonucleotide 5'-TGTCAAAGGATCCATGGACTAAGATCATG-3', which is specific for exon 4 of the mouse FceRI o~ chain gene and does not cross-react with the transgenic mRNA.
Mast Cell Cultures Derived from Bone Marrows. Mast cells from
transgenic or C57BL/6J mice were prepared from bone marrow cells according to the method described by Razin et al. (17) . In brief, bone marrow cells were collected from mouse femur and tibia and cultured at 3 X 105 cells/ml in Razin's medium (RPMI-1640 medium with 10% FCS, 50 IxM 2-ME, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 100 U/ml penicillin/streptomycin) supplemented with 20% WEHI-3B cell supernatant (American Type Culture Collection, Rockville, MD). Culture medium was changed weekly. After 3 wk in culture, the majority of the bone marrow cells differentiated into mast cells. Mast cells were identified by the presence of basophilic granules in the cytoplasm of the cells after May Grtinwald/Giemsa staining.
The Binding of IgE to Mast Cells Analyzed by Flow Cytometry.
BMMC from transgenic and normal C57BL/6J mice were used in flow cytometric analyses. 2 • 10 s BMMC in 50 IM of staining buffer (PBS with 2% FCS, 0.1% sodium azide) were incubated for 1 h at 4~ with 2.5 Dg of biotinylated human IgE (Serotec Ltd., Oxford, UK) or mouse IgG (18), followed by incubation with streptavidin-phycoerythyrin (Becton Dickinson & Co., Mountain View, CA) for 20 min at 4~ Cell-bound IgE was analyzed via flow cytometry using the FACScan | program (Becton Dickinson & Co.). Specificity of human IgE binding was studied by incubating BMMC with unbiotinylated human IgE before biotinylated human IgE, which was detected by streptavidinphycoerythrin. The possible cross-reactivity of mouse IgE with human FceRI ~x chain (6) were incubated overnight with 1 Ixg/ml biotinylated human or mouse IgE in 5 ml of culture medium. Cells were then solubilized in CHAPS buffer according to the method described by Kinet et al. (19) with some modifications. In brief, cells were lysed at 4~ in 0.2 ml of 10 mM CHAPS lysing buffer containing inhibitors for phosphatases and proteolytic enzymes (l mM sodium orthovanadate, 12.5 mM sodium fluoride, 0.1 mM zinc chloride, 2 mM EDTA, 2 mM EGTA, 1 mM PMSF, 20 btg/ml aprotinin, and 10 Ixg/ml leupeptin). IgE-bound FceRI in cell lysates was recovered by overnight incubation at 4~ with 0.1 ml packed volume of precleared avidin-conjugated agarose beads (Pierce Chemical Co., Rockford, lL). The IgE-FceRI complex was eluted in SDS-PAGE loading buffer, separated on 12.5% SDSpolyacrylamide gels under reducing condition, and then transferred to membranes (PolyScreen; New England Nuclear, Boston, MA). The mouse FceRI [3 and y chains were detected by the rat FceRI ~3 chain-specific mAb and the rabbit serum specific for the mouse Fc~RI y chain (20) , respectively. Antibody binding was detected with chemiluminescent reagents (ECL kit; Amersham Corp., Arlington Heights, IL).
Detection of Tyrosine Phosphorylation Triggered by Cross-linking of
FcERI. BMMC (2 X 106 cells) from transgenic or C57BL/6J mice were incubated either with 1 ~g/ml of anti-nitro-iodohydroxyphenyl (NIP) human IgE (Serotec Ltd.) or anti-dinitrophenyl (DNP) mouse IgE (18) for 2 h at 37~ in PBS. Cells were then rinsed with PBS and incubated for 2 min at 37~ with 40{} ng/ml NIP-BSA or DNP-BSA, respectively. BMMC incubated with IgE but not with the corresponding antigens were used as negative controls. Cells were lysed in SDS-PAGE loading buffer, and proteins were separated and transferred to PolyScreen membranes as mentioned above. Phosphotyrosine was detected by the phosphotyrosine-specific mouse mAb 4G10 (Upstate Biotechnology, Inc., Lake Placid, NY), and antibody binding was detected with chemituminescent reagents from Amersham Corp.
Detection of Tyrosine Phosphorflation on FcERI Subunits Triggered by the Cross-link of FcERl. BMMC (107 cells) from transgenic or
C57BL/6J mice were incubated overnight with 1 I~g/ml biotinylated anti-NIP human IgE or anti-DNP mouse IgE in 5 ml of culture medium. The human or mouse IgE-coated BMMC were incubated with 1 Ixg/ml NIP-BSA or DNP-BSA, respectively, for 2 rain at 37~ in PBS to cross-link IgE-bound Fc~Rl. BMMC were solubilized in CHAPS buffer as described earlier, and IgE-bound FceRI in cell lysates was recovered by avidinconjugated agarose beads. Proteins eluted from agarose beads were separated by reducing S1)S-PAGE, transferred to PolyScreen membranes, and phosphotyrosines were detected. BMMC treated similarly with unbiotinylated human or mouse IgE did not show any signals in phosphotyrosine detection, confirming the specificity of the immunoprecipitations.
IgE-mediated BMMC Degranulation Detected by the Release of [3-Hexosaminidase. Mast cell degranulation triggered by IgE and
antigens was carried out according to the methods described by Yen et al. (21) . BMMC (5 X I0 s cells) in 0.5 ml Tyrode's buffer were sensitized with 1 p~g/ml anti-NIP human IgE or anti-DNP mouse lgE for 1 h at 37~ After two rinses with Tyrode's buffer to remove unbound IgE, degranulation was triggered by 10-rain incubation with 50 ng/ml of the antigens, DNP, or NIP conjugated to BSA. Degranulation was assayed by measuring the enzyme activity of released [3-hexosaminidase using a colorimetric assay (22) . Spontaneous 13-hexosaminidase release was measured in samples not treated with IgE or antigen. Total 13-hexosaminidase was measured after lysing cells by sonication. Percentage of 13-hexosaminidase release was calculated as: (13-hexosaminidase in supernatant/total [3-hexosaminidase) • 100.
Passive Cutaneous Anaphylaxis. Passive cutaneous anaphylaxis was performed in mice according to the method described by Saloga et al, (23) . Transgenic mice and normal C57BL/6J mice were injected intradermally on the dorsal side with 500 ng NIPspecific human lgE in 25 txl saline, and on the ventral side with 25 Ixl saline for comparison. 2 h later, NIP-BSA conjugates (0.5 mg) plus 1% Evans blue in 250 txl saline i.v. was injected. Mice were killed 20 rain later, and cutaneous anaphylaxis was assessed visually by the blue dye leakage from blood vessels into the skin. Mouse IgE-mediated anaphylaxis was carried out similarly using DNP-specific mouse IgE and DNP-BSA.
Results
Mast Cell-specific Transcription of the Transgene Encoding the
Human FcERI ce Chain. W e previously cloned the h u m a n F c e R I ci chain gene and showed that the h u m a n gene is similar in genomic structure to that of the rodent (16) . T h e h u m a n F c e R I 0r chain gene spans over a region of 5.9 kb and contains 5 exons. As s h o w n in Fig. 1 , an 11.4-kb D N A fragment covering the entire h u m a n cx chain gene with an 1.3-kb p r o m o t e r region and a 4.2-kb 3' flanking region was used to generate transgenic mice. Transcription of the transgene in different organs and in mast cells from transgenic mice was studied by N o r t h e r n blot hybridization. Mast cells used in the study were B M M C . Transgenic m R N A was detected only in B M M C , but not in the different organs from transgenic mice (Fig. 2 A) . Tissue distrib u t i o n of transgenic m R N A was identical to that transcribed by the endogenous mouse Fc~RI ci chain gene (Fig. 2 B) . T h e data suggest that the 1.3-kb promoter region of the h u m a n Fc~RI cl chain gene is sufficient for regulating proper tissue-specific expression.
Cell Surface Expression of the Human FcERI cr Chain on
Transgenic Mast Cells. Cell surface expression of the transgenic h u m a n Fc~RI ci chain on mast cells was assessed by its specific b i n d i n g to h u m a n IgE. H u m a n IgE was s h o w n to bind to B M M C from transgenic mice, but not to that from C57BL/6J mice in flow cytometric analyses (Fig. 3, C and D). T h e b i n d i n g of biotinylated h u m a n IgE to transgenic B M M C was completely abrogated w h e n cells were pretreated with unbiotinylated h u m a n lgE, suggesting the specificity in the binding to h u m a n IgE (Fig. 3 E) . 125I-human IgE was also used in receptor-binding assays to determine the b i n d i n g affinity o f transgenic FcERI toward h u m a n IgE. As s h o w n in Table 1 , the n u m b e r of transgenic FceRI on B M M C was 4.7 X 104/ce11, and the h u m a n IgE dissociation constant was 6.4 nM. These values were comparable to those of the mousee Fc{RI (1.8 X 10S/cell, Ka = 2.19 nM) determined in the same experiment using mouse IgE (Table 1) , and were also consistent with the values reported previously for h u m a n or mouse F c e R I on mast cells (24, 25) . T a k e n together, the specific b i n d i n g of h u m a n IgE to B M M C from transgenic mice as shown in flow cytometric analyses and in 12sI-IgE-binding assays confirms the cell surface expression of the h u m a n F c e R I oL chain. Mouse F c e R I on mast cells was assayed similarly using mouse IgE. Mast ceils from both transgenic and C57BL/6J mice were shown to bind to mouse IgE in flow cytometric analyses (Fig. 3, A and B) . However, the a m o u n t o f cellb o u n d mouse IgE on transgenic mast cells was less than that on the nontransgenic B M M C . Consistent with this finding, 125I-IgE-binding studies also showed that mouse F c e R I receptor n u m b e r on transgenic B M M C was reduced, whereas its mouse I g E -b i n d i n g affinity was unchanged (Table 1) . T h e results suggest that the cell surface expression of mouse F c e R I was reduced on B M M C from transgenic mice. This decrease in mouse FceRI level on transgenic mast cells could be due to the competition between the h u m a n and mouse (x chains in coupling with the mouse y a n d / o r 13 chains. T h e possibility that the h u m a n F c e R I 0t chain forms a chimeric receptor with mouse y a n d / o r [3 chains has also b e e n suggested by previous transfection studies (9, 10, 26-28).
The Transgenic Human FcERI ee Chain Is Complexed with the Mouse [3 and 3, Chains.
T h e h u m a n F c e R I 0L chain has been shown in transfected cells to require at least the ot and y chains for cell surface expression (10, (26) (27) (28) . In this transgenic model, proteins that are complexed with the transgenic h u m a n F c e R I cx chain were analyzed in i m m unoprecipitation studies. T o maintain the integrity of the FcERI receptor complex, B M M C were lysed with C H A P S buffer according to the m e t h o d of Kinet et al. (19) . T h e transgenic h u m a n F c e R I or the endogenous mouse FceRI was immunoprecipitated via its binding to h u m a n or mouse IgE, respectively. T h e m A b specific for the rat Fc~RI [3 chain detected the mouse 13 chain in mouse F c e R I i m m unoprecipitates with .an apparent molecular mass o f 30 kD (Fig. 4) . Interestingly, the mouse FceRI 13 chain was also present in the transgenic h u m a n F c { R I immunoprecipitates (Fig. 4) . T h e mouse Fc~RI ",/chain, which was ~1 0 kD in size, was detected with rabbit sera specific for the mouse Fc~RI ~/ chain (20) . Similarly, the mouse y chain was found in both the immunoprecipitates of the transgenic h u m a n F c e R I and the mouse F c e R I (Fig. 4) . T h e results demonstrated that the h u m a n Fc~RI et chain is coupled with both the mouse 13 and "y chains to form a chimeric h u m a n / m o u s e receptor.
Normal Tyrosine Phosphorylation Triggered by Cross-linking the Transgenic FceRI.
Activation and degranulation of mast cells via FceRI aggregation has been shown to involve early signaling events including activation o f protein tyrosine kinases (29) (30) (31) (32) (33) . T h e function of the transgenic FceRI in initiating tyrosine phosphorylation in B M M C was investigated. Transgenic h u m a n Fc~RI was cross-linked by first binding to a n t i -N I P h u m a n IgE (34), followed by interacting with the multivalent antigen N I P -B S A . Mouse endogenous Fc~RI was aggregated similarly by a n t i -D N P mouse IgE (18) (Tg) BMMC was immunoprecipitated with mouse IgE (m) or human IgE (h) as described in Materials and Methods. The mouse FceRI ~ chain was detected with anti-rat 13 mAb (20) , whereas the 3' chain was detected by using the 3' chain-specific rabbit serum (21).
phosphorylations was detected 2 rain after cross-linking of mouse FceRI on B M M C from transgenic or control C57BL/6J mice (Fig. 5) . Human IgE and N I P -B S A also triggered pronounced tyrosine phosphorylations in transgenic B M M C but not in C57BL/6J B M M C , suggesting that the human IgE-induced signaling events were mediated specifically by the transgenir human FceRI (Fig. 5) . The patterns of phosphorylated proteins induced by aggregation of the transgenic human FceRI or the endogenous mouse FceRI appeared to be similar (Fig. 5) . Recent reports have shown that aggregation of Fc~RI leads to significant tyrosine phosphorylation of the 13 and ~/ subunits, which recruit other signaling molecules for cellular activation (29, 31) . Tyrosine-phosphorylated proteins in immunoprecipitates of the transgenic FceRI were therefore examined. Proteins o f ~3 0 and 10 kD, which correspond by size to the FceRI [3 and y chains, respectively, were barely detectable in immunoprecipitates o f uncross-linked mouse FceRI (Fig. 6 ). Upon aggregation o f mouse Fc{RI, these proteins were dramatically enhanced in tyrosine phosphorylation (Fig. 6 ). Cross-linking of the transgenic FceRI also showed significant tyrosine phosphorylation of the 30 and 10 kDa proteins (Fig. 6 ). Human IgE does not bind to mouse Fc~RI and therefore had no effect on Fc~RI on nontransgenic BMMC. Taken together, the data suggest that the transgenic human Fc~RI is functional in triggering mast cell activation. The coupling of mouse [3 and y chains with the transgenic human ot chain appears not only important for cell surface expression, but also for the proper function of the chimeric receptor.
Degranulation of Transgenic Mast Cells Triggered by Crosslinking the Human FcERI ee Chain. With this transgenic
model, we address the question whether the human/mouse chimeric receptor is competent in eliciting mast cell degranulation. Mast cells were prepared from transgenic mice, and degranulation was triggered by first allowing the binding of IgE to Fc~RI on mast cells, followed by cross-linking receptor-bound IgE with a multivalent antigen. Release of [3-hexosaminidase upon degranuladon was measured. The NIP-specific human IgE and N I P -B S A triggered a specific release of [3-hexosaminidase from transgenic BMMC, but not from control C57BL/6J B M M C (Fig. 7) . The D N P - (Fig. 7) . The results indicate that the FceRI with the transgenic human o~ chain is responding to human IgE, and is functional in mediating murine mast cell exocytosis. Mast cells from transgenic mice, however, can still respond to mouse IgE in exocytosis.
Passive Cutaneous Anaphylaxis of Transgenic Mice Induced by Human IgE and Antigens. To assess whether the transgenic
Fc~RI with the human o~ chain can respond to human lgE in mast cell degranulation in vivo, passive cutaneous anaphylaxis was carried out in transgenic mice. Mice were intradermally injected wtih human or mouse IgE, followed by intravenous injection of antigens and Evans blue. In transgenic mice, human IgE and its antigen NIP-BSA induced a specific leak of Evans blue into the skin at the site ofintradermal injection. This blue dye leakage was not observed in control C57BL/6J mice (Fig. 8) . The extravasation o f the dye is a result of blood vessel dilation, which is induced by mediators released from mast cells in degranulation. Mouse monoclonal IgE and its antigen D N P -B S A caused a similar leak of Evans blue in both transgenic mice and control C57BL/6J mice (Fig. 8) clear in vivo demonstration that transgenic mice can respond to human IgE in anaphylaxis.
Discussion
Human FceRI expression on the cell surface is known to require at least the ot and y chains (10, (26) (27) (28) . iThe ability of the "y chain to allow surface expression o f the Fc~RI chain is analogous to the role of the ~ chains in the expression of the T C R -C D 3 complex, although the molecular mechanism of the FceRI assembly is still unclear. Both the FceRI c~ and y chains are highly conserved at the transmembrane portions, which are suggested to be important for proper assembly o f the FceRI receptor complex (10, 28) . In contrast, the role of the 13 chain for cell surface expression and activation of human FceRI has been unclear. Questions have therefore been raised regarding to the importance of the Fc~RI 13 chain in humans and the possible difference in FceR1 receptor complex between humans and rodents. We have demonstrated here in a transgenic model that the transgenic FceRI, which elicits normal mast cell activation and degranulation, is composed of the human c~ chain and the mouse 13 and y chains. The data suggest that the 13 chain may play a role in the biological functions of FceRI. The importance of the 13 chain has also been suggested by the finding that it is also associated with the IgG Fc receptor type III, which mediates effector functions similar to that of FceRI (35) . A correlation o f mutations on the FceRI [3 chain gene with atopic dermatitis has also been reported recently (36, 37) .
The transgenic FceRI in which only the ot chain was of human origin was shown to bind to human IgE specifically. This is consistent with previous in vitro studies showing that the ot chain confers entirely the IgE-binding specific- ity, whereas the 13 and y chains are responsible for signaling events (6, 11, 29, 31, 38, 39) . The extracellular portion o f the FceRI ~ chain has been shown to display less conservation between species (10). This structural diversity could be responsible for the species specificity seen in IgE-FceRI interaction.
The proper assembly and coordination of the different subunits of FceRI is essential for its function in triggering mast cell degranulation (1). In this regard, the FceRI c~ chain receives external signals through IgE binding, whereas the FceRI y chain plays a critical role in signal transduction (11, 29, 31, 38, 39) . Although the human FceRI o~ chain in association with mouse y chains has been shown to trigger limited early signaling events in mast cell lines, the induction of cellular degranulation has not been demonstrated (26, 39, 40) . W e showed with this transgenic model that the human/mouse chimeric FceRI is functional in mediating mast cell activation and degranulation. The results suggest that the proper conformation of the receptor complex is maintained in the transgenic FceRI.
Allergic diseases affect 20% of the population and are an important cause of morbidity and mortality. The cell typespecific expression and the key role in mast cell exocytosis make FceRI an attractive drug target for treatment of IgEdependent allergies. However, animal studies are limited by the species specificity in IgE-FceRI interaction. We have demonstrated here in a transgenic model that the human FceRI o~ chain not only confers the specificity in human IgE binding but also can reconstitute a functional FceRI to trigger mast cell degranulation in vitro and in vivo. These transgenic mice with a "humanized" FceRI could be a valuable model for developing drugs that block human IgE from binding to its receptor.
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